Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947059 | 0.88 | PTGES (0.46) | MAPTABL1PTGESEPHX2 | |
| SCHEMBL9898727 | 0.87 | PTGES (0.49) | MAPTALDH1A1GLAGAAABL1 | |
| SCHEMBL9945038 | 0.86 | ALDH1A1 (0.52) | MAPTALDH1A1PKMKDM4EMAPK1 | |
| SCHEMBL9946856 | 0.86 | MAPT (0.53) | MAPTALDH1A1GLAGAAABL1 | |
| SCHEMBL9946597 | 0.77 | MAPT (0.48) | MAPTABL1PTGESEPHX2 | |
| SCHEMBL9946643 | 0.76 | PTGES (0.49) | MAPTABL1PTGESEPHX2 | |
| SCHEMBL9945022 | 0.74 | ALDH1A1 (0.43) | MAPTALDH1A1GAAPKMKDM4E | |
| SCHEMBL9946656 | 0.74 | PTGES (0.48) | MAPTGAAABL1PTGESEPHX2 | |
| SCHEMBL9898485 | 0.74 | PTGES (0.47) | MAPTALDH1A1GLAGAAABL1 | |
| SCHEMBL9944801 | 0.74 | ALDH1A1 (0.55) | MAPTALDH1A1PKMKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076673-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | MAPT 4336/4885ALDH1A1 126/4885GLA 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.